Several groups have shown that MYC is a critical effector of mutant KRAS in pancreatic ductal adenocarcinoma (PDAC) [22, 23, 24, 25], prompting us to examine if NUAK1 might be required to support oncogenic proliferation in this context. Here, KRAS is linked to pancreatic ductal adenocarcinoma.